These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 12548585

  • 1. Bisphosphonates and metastatic breast carcinoma.
    Lipton A.
    Cancer; 2003 Feb 01; 97(3 Suppl):848-53. PubMed ID: 12548585
    [Abstract] [Full Text] [Related]

  • 2. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y.
    Cancer J; 2001 Feb 01; 7(5):377-87. PubMed ID: 11693896
    [Abstract] [Full Text] [Related]

  • 3. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ, Mancini I.
    Support Care Cancer; 2002 Jul 01; 10(5):399-407. PubMed ID: 12136223
    [Abstract] [Full Text] [Related]

  • 4. Recommendations for zoledronic acid treatment of patients with bone metastases.
    Berenson JR.
    Oncologist; 2005 Jan 01; 10(1):52-62. PubMed ID: 15632252
    [Abstract] [Full Text] [Related]

  • 5. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R.
    Clin Cancer Res; 2003 Jul 01; 9(7):2394-9. PubMed ID: 12855610
    [Abstract] [Full Text] [Related]

  • 6. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
    Rosen LS, Gordon DH, Dugan W, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE.
    Cancer; 2004 Jan 01; 100(1):36-43. PubMed ID: 14692022
    [Abstract] [Full Text] [Related]

  • 7. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
    Maxwell C, Swift R, Goode M, Doane L, Rogers M.
    Clin J Oncol Nurs; 2003 Jan 01; 7(4):403-8. PubMed ID: 12929273
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
    Body JJ.
    Cancer; 2003 Feb 01; 97(3 Suppl):859-65. PubMed ID: 12548587
    [Abstract] [Full Text] [Related]

  • 11. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ.
    Cancer; 2003 Feb 01; 97(3 Suppl):887-92. PubMed ID: 12548591
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE.
    J Clin Oncol; 2006 Oct 20; 24(30):4895-900. PubMed ID: 17001071
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH.
    Clin Breast Cancer; 2005 Jun 20; 6(2):125-31. PubMed ID: 16001990
    [Abstract] [Full Text] [Related]

  • 14. The role of bisphosphonates in breast cancer.
    Coleman RE.
    Breast; 2004 Dec 20; 13 Suppl 1():S19-28. PubMed ID: 15585379
    [Abstract] [Full Text] [Related]

  • 15. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S.
    J Clin Oncol; 2005 May 20; 23(15):3314-21. PubMed ID: 15738536
    [Abstract] [Full Text] [Related]

  • 16. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [Abstract] [Full Text] [Related]

  • 17. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
    Saad F.
    Semin Oncol; 2002 Dec 15; 29(6 Suppl 21):19-27. PubMed ID: 12584691
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonate therapy for patients with breast carcinoma.
    Plunkett TA, Rubens RD.
    Cancer; 2003 Feb 01; 97(3 Suppl):854-8. PubMed ID: 12548586
    [Abstract] [Full Text] [Related]

  • 19. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
    Smith MR.
    Cancer Treat Rev; 2005 Feb 01; 31 Suppl 3():19-25. PubMed ID: 16229955
    [Abstract] [Full Text] [Related]

  • 20. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.
    Acta Pol Pharm; 2002 Feb 01; 59(6):478-82. PubMed ID: 12669777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.